“At last, through social media and patient-generated data, we can put the final piece of the puzzle into place and genuinely understand the real lived experience of people managing illness, injury and disorders
Michelle Gallaher, chief executive
Opyl Limited (ASX:OPL) has launched a new company name and brand, heralding its entry into the rapidly expanding global digital health and artificial intelligence (AI) market.
Combining new technologies and healthcare expertise, Opyl’s key offerings include optimising clinical study design and recruitment strategies.
The rebranded and refocused company, formerly known as ShareRoot Limited, is using AI to better understand the patient experience
Following a strong shareholder vote at the company's recent annual general meeting, the new name of Opyl Limited was approved.
Reflective of new strategy
Opyl's former name and brand were established in the US in 2013 and the new name better reflects the company's new strategy.
The Social Science brand within the ShareRoot group of companies will also be retired.
Opyl is designed to use AI-assisted technologies to provide biopharma and health organisations with an opportunity to collect and analyse the significant volume of clinical health data and real-world data.
The continuous flow of health data created in clinical settings and by patients in the natural course of each day is exceptionally large with the vast proportion of it underutilised by medical researchers and developers.
Accessing public and consented de-identified health and wellness data created by patients willingly shared to social media and analysing it using AI is Opyl’s point of difference.
"Giving patients more control"
Chief executive officer Michelle Gallaher said: “At last, through social media and patient-generated data, we can put the final piece of the puzzle into place and genuinely understand the real lived experience of people managing illness, injury and disorders.
“Hearing millions of patients’ and carers’ voices for the first time in their own words shared to social media platforms is an extraordinary insight that few in the health sector have been able to access until now.
“Patient stories and information shared to social networks gives us an ability to understand what their needs are and how they are not being met, identifying gaps where new technologies can be developed, predict the spread of infectious diseases, identify shortcomings in health and wellness education, improve compliance, identify new clinical intervention opportunities and opening up a novel way for patients to participate in medical research as partners.
“Our vision is to give patients control and agency over all their health data, not just electronic health records”.
Data technologies to personalise health experience
Melbourne design studio Malt Creative worked with Opyl’s internal design team to develop the company’s new brand identity.
Gallaher added: “Digital and data technologies will play an increasingly disruptive role in transforming health, clinical research and activating patients to be partners in their health care.
“I’m very excited to explore and bring into practice evolving digital tools that can personalise the health and wellness experience within a considered and ethical framework, where patients are recognised as partners and are empowered and incentivised to manage their data directly.
“We are very excited at the addition of AI-powered technologies to the STEMM-specialist social media content creation and management services we currently offer.”